Global Urticaria Drugs Market 2022-2026
Technavio has been monitoring the urticaria drugs market and it is poised to grow by $ 1.31 bn during 2022-2026, accelerating at a CAGR of 10.35% during the forecast period. Our report on the urticaria drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increase in incidence of urticaria, guidelines for the management of urticaria patients, and increasing approval of the drugs for urticaria.
The urticaria drugs market analysis includes application segment and geographic landscape.
Technavio's urticaria drugs market is segmented as below:
- Acute urticaria
- Chronic urticaria
- North America
- Rest of World (ROW)
This study identifies the introduction of biologics for the treatment of urticaria as one of the prime reasons driving the urticaria drugs market growth during the next few years. Also, international guidelines for diagnosis and management of urticaria and increasing research funding will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on urticaria drugs market covers the following areas:
- Urticaria drugs market sizing
- Urticaria drugs market forecast
- Urticaria drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading urticaria drugs market vendors that include Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Sanofi, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., United BioPharma Inc., and Viatris Inc.. Also, the urticaria drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.